Lumenis

Baring To Acquire Lumenis

Top Aesthetic Laser Provider Sold

Baring Private Equity Asia (BPEA) has agreed to acquire Lumenis, a provider of specialty energy-based medical devices across the fields of aesthetics, urology, ophthalmology, ENT and gynecology from XIO. The transaction values Lumenis at an enterprise value of over $1 billion.

Lumenis has a presence in over 100 countries and close to 1,500 employees worldwide. The Asia Pacific region is its largest market, together with a strong presence in North America and EMEA.

Nonablative Resurfacing

Main Image: 
Nonablative Resurfacing

The new Lumenis ResurFX is a 1565nm, erbium-doped nonablative fractional laser system, which can be used for the treatment of fine lines and wrinkles, texture irregularities and pigmentation problems. The standalone desktop platform offers customized treatment parameters that allow providers to choose from more than 600 combinations of shape, size, density and energy delivery. The ResurFX is effective in a single pass, does not require disposables and features CoolScan technology for precise delivery with continuous cooling.

No, don't share this with BeautyEtc
Article free tagging: 
Articles: 

Skin Resurfacing: Lumenis SCAAR FX

Main Image: 
Lumenis SCAAR FX

Lumenis has added the new SCAAR FX mode to its UltraPulse fractional CO2 laser for the treatment of surgical and acne scars. With the ability to precisely deliver up to 150mJ per pulse per spot, the SCAAR FX can deliver energy up to 4mm deep into the skin tissue. “Hypertrophic scars consist of contracted tissue of varying thicknesses.

Articles: 

Lumenis and the Wellman Center Join Forces

Medical laser developer Lumenis has entered into a joint research, development and licensing agreement with the Wellman Center for Photomedicine at Massachusetts General Hospital, an academic research facility dedicated to light-based biomedical research. The goal of the partnership is to develop new treatments that will progress the field by expanding indications and improving patient outcomes.